Sanofi: MS drug Lemtrada has positive trial result MarketWatch FR) said Monday the results of a late-stage trial of multiple sclerosis drug Lemtrada were positive. The two-year study compared the experimental therapy, also known as alemtuzumab, against Merck KGaA's MS medicine Rebif in 581 patients with ... See all stories on this topic » |